BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, today announced that, on March 3, 2025, it made a grant of restricted stock units ("RSUs") covering 220,844 shares of its Class A common stock to Dan Zamansky. The grant was offered as material inducement to Zamansky's employment as Amwell's chief product and technology officer. The RSUs become vested as follows, subject to Zamansky's continued employment through each vesting date, except as noted below: 25% of the RSUs will vest on the six-month anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro-rata increments every three (3) m

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, announced Dan Zamansky, an industry leader in innovation and technology, as the company's new chief product and technology officer, effective today. Zamansky will lead the company's product and R&D organizations. He will focus on the comprehensive technology-enabled care platform Amwell offers payers and health systems to provide individuals with better access to more convenient, affordable and effective care. In addition, as more people seek care online and more clinical programs are available, Zamansky will ensure the Amwell platform continues to evolve and provide clients with an integr

BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading technology-enabled care platform provider, announced that on Feb. 18, Amwell made grants of RSUs covering an aggregate of 16,737 shares of its Class A common stock to four new employees. The grants were offered as material inducement to the employees' employment with Amwell. The RSUs will vest as follows, subject to the applicable employee's continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first

Wells Fargo upgraded Amwell from Equal Weight to Overweight and set a new price target of $15.00

Morgan Stanley downgraded Amwell from Overweight to Equal-Weight and set a new price target of $2.50 from $5.00 previously

TD Cowen downgraded Amwell from Outperform to Market Perform and set a new price target of $2.50 from $5.00 previously

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

144 - American Well Corp (0001393584) (Subject)

8-K - American Well Corp (0001393584) (Filer)

S-8 - American Well Corp (0001393584) (Filer)

BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value.   Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv

Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol

ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ

BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the fourth quarter and full year 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Feb. 12. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/zsp4abpw. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. Abo

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock market trading hours on Wednesday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Am

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the third quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Oct. 30. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay of the call will

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G - American Well Corp (0001393584) (Subject)

SC 13G - American Well Corp (0001393584) (Subject)